Given the potent enhancement of anti-PD1 efficacy by oral l-fuc administration in mice, we investigated whether tumor fucosylation or total/fucosylated HLA-DRB1 might correlate at all with responsiveness to anti-PD1 therapy in human patient biopsies, as the identification of preliminary correlations might support their subsequent development into predictive biomarkers for anti-PD1 responsiveness. This evidence concerns the gene PDCD1 and neoplasm.